Zhu Yan, Wu Shikai
Department of Oncology, Peking University First Hospital, Beijing 100034, China.
Zhongguo Fei Ai Za Zhi. 2020 Oct 20;23(10):889-896. doi: 10.3779/j.issn.1009-3419.2020.101.33.
Small cell lung cancer (SCLC) is a type of malignancy with poor prognosis, and no advance in medication has been made for about 30 years except immune checkpoint inhibitor (ICI), which demonstrated efficacy in recent years. The response rate of programmed death-1 (PD-1) inhibitor alone or its combination with cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor as subsequent therapy was 10%-33% and the response duration was persistent. The combination of programmed death ligand-1 (PD-L1) inhibitor with chemotherapy resulted in longer survival versus chemotherapy alone. Nevertheless, comparing with immunotherapy-sensitive tumors such as non-small cell lung cancer (NSCLC), efficacy in SCLC is still unsatisfied and this is maybe associated with its immune inhibitory characteristics. This review describes the current research about immune characteristics of SCLC, including tumor infiltrating of lymphocytes (TIL) and immune inhibitory cells, PD-L1 and major histocompatibility complex (MHC) expression in tumor as well as changes of peripheral immune cells. We also review the prognostic and predictive values of these immune characteristics. .
小细胞肺癌（SCLC）是一种预后较差的恶性肿瘤，除免疫检查点抑制剂（ICI）外，近30年来药物治疗一直没有进展，而ICI近年来显示出疗效。程序性死亡-1（PD-1）抑制剂单独使用或与细胞毒性T淋巴细胞抗原-4（CTLA-4）抑制剂联合作为后续治疗的缓解率为10%-33%，且缓解持续时间较长。程序性死亡配体-1（PD-L1）抑制剂与化疗联合使用比单纯化疗能延长生存期。然而，与免疫治疗敏感的肿瘤如非小细胞肺癌（NSCLC）相比，SCLC的疗效仍不尽人意，这可能与其免疫抑制特性有关。本综述描述了目前关于SCLC免疫特征的研究，包括淋巴细胞肿瘤浸润（TIL）和免疫抑制细胞、肿瘤中PD-L1和主要组织相容性复合体（MHC）的表达以及外周免疫细胞的变化。我们还综述了这些免疫特征的预后和预测价值。
